Objectives: This study aims to assess whether the expression of Twist1, 
According to morphologic, genetic, and clinical characteristics, HM is subcategorized into partial hydatidiform mole (PHM) as well as a complete hydatidiform mole (CHM). Morphologically, hydropic abortion (HA) can simulate HM. Despite the well-defined histopathologic criteria, differentiation of HA from HM and CHM from PHM remains challenging in clinical practice. 7 Clinical distinction of CHM and PHM has important therapeutic and prognostic implications since the predicted risk of developing persistent gestational trophoblastic disease is different with each type (10%-30% or 1%-7%, respectively). 8 Histologic distinction of HM from nonmolar pregnancy, as well as the differentiation of CHM and PHM, is strenuous due to the overlapping morphologic criteria, especially in the first trimester. Previous studies have reported a low rate of concordance among pathologists, as well as a high rate of misclassification. 9, 10 Currently, and thanks to the recent advances in genetic and molecular research, a number of ancillary techniques, including flow cytometry (FC), digital image analysis, and p57 immunostaining, have been proposed to establish confirmatory diagnosis of HM. 8, [11] [12] [13] [14] [15] FC typically targets the identification of DNA ploidy of a large number of cells rapidly. It particularly helps the diagnosis of PHM cases, which characteristically comprise an androgenic triploid chromosomal complement. However, FC cannot reliably discern HA from CHM since both typically comprise diploid or near-diploid chromosomal complements. In addition, FC remains an expensive and time-consuming technique, requiring skilled operators and special facilities and, therefore, cannot be routinely used in most centers. 16 p57 immunostaining particularly targets the expression of the p57KIP2 gene, which is a well-known paternally imprinted gene that is dominantly expressed from the maternal allele. 17 Expression of the p57 gene is typically absent in CHM but fairly present in both PHM and normal trophoblasts. The technique is easy and affordable; however, it is only useful in affirming CHM and cannot be used to distinguish PHM from other nonmolar gestations. 10, 18 With the existing limitations of the discussed molecular targets, current research efforts are focused on identifying reliable differential targets for the distinction and classification of HM.
The process of placental formation involves a set of cellular events, including the essential epithelial-mesenchymal transition (EMT), and trophoblastic differentiation and invasion. 19 EMT requires the downregulation of cell junctional proteins, including their prominent family, cadherins. 20 The latter are mediators of cell-to-cell adhesion in epithelial tissues and regulators of trophoblast cell behavior in placental development. With the reduction of cadherin expression, the trophoblast acquires a mesenchymal phenotype characterized by proliferative and invasive capacity, facilitating implantation and fetal-maternal interaction. 20 Indeed, E-cadherin expression was diminished from the first to the third trimesters in standard term placenta within normal pregnancies, 21 and this alteration might be attributed to E-cadherin downregulation in the transition of cytotrophoblasts to syncytiotrophoblasts. 22, 23 Repression of cadherin expression is mediated by cytokines through the modulation of a number of transcription factors. 24 Among these factors is the Twist1 protein, which not only induces EMT by the downregulation of cadherins but also activates the transcription of genes characteristic of the mesenchymal state. 19 Although twist expression has not been detected in villous blood vessels, it has been found in villous mesenchyme, indicating that it may stimulate the mesenchyme-endothelial transition in those cells. 19 Ki-67 protein is another protein that plays a role in the process of trophoblast differentiation. The protein is normally expressed during all active phases of the cell cycle (G1, S, G2, and mitosis) and is mainly expressed by cytotrophoblasts, especially in zones forming trophoblastic columns. The absence of Ki-67 protein expression in resting cells (G0) indicates that this protein is an excellent marker that reflects the tissue propagation compartment and hence could be of value in determining the biological behavior of GTDs. 25 In the present study, we tested whether the expression of Twist1, Ki-67, and E-cadherin can guide the differential diagnosis of HA, PHM, and CHM, particularly in problematic cases.
Materials and Methods

Case Selection
In this retrospective study, 55 formalin-fixed, paraffin-embedded gestational products, representing CHM, PHM, or HA, were randomly retrieved from the archive of the Department of Pathology, faculty of medicine, Minia University, Egypt, between December 2015 and October 2016. The original identification of CHM, PHM, and HA cases was based on histologic evaluation of H&E-stained sections, which was performed according to the criteria described by Paradinas. 26 Confirmation of the original diagnosis was done by ploidy analyses using flow cytometry and p57 immunohistochemistry.
Flow Cytometry
For DNA analysis, a single-cell suspension from formaldehyde-fixed, paraffin-embedded tissue samples was prepared according to Hedley. 27 Three sections of 5-µm thickness each were cut, deparaffinized with xylene (three incubations for 30 minutes each with 10 mL of a descending concentration of xylene), rehydrated in descending graded ethanol (10 mL of 100%, 95%, 70%, and 50%, 10 minutes each at room temperature), and then washed twice in phosphate-buffered saline (PBS; 0.1 mol/L, pH 7.4). The mixture was then incubated in a water bath containing 0.5% pepsin (Sigma-Aldrich, St Louis, MO) at pH 1.5 and 37°C for 90 minutes with transient tapping every 5 minutes for mixing. Afterward, the tissue was filtrated through a 50-mL pore size nylon mesh and washed twice in PBS containing trypsin inhibitor and ribonuclease A (CycleTest PLUS DNA Reagent kit; Becton-Dickinson, Sunnyvale, CA) to stop the action of pepsin and digest RNA. Nuclear staining for DNA content was done using the CycleTest PLUS DNA Reagent kit (Becton-Dickinson) according to the manufacturer's protocol. The stained samples were analyzed by a flow DOI: 10.1093/ajcp/aqy012 © American Society for Clinical Pathology cytometer (Facscan; Becton-Dickinson). Normal human peripheral blood lymphocytes were used to identify the normal diploid peak that acted as a reference peak for subsequent analysis. At least 10,000 cells were acquired by a flow cytometer at a rate of 100 to 300 cells/s for each sample, and data were presented as DNA distribution histograms. Data were analyzed using Modfit software (Becton-Dickinson). The quality of DNA was controlled by a coefficient of variation of less than 7%.
Interpretation of DNA Histograms
Sample histograms showing a single G0/G1 peak were considered diploid. Samples that exhibited two distinct G0/ G1 peaks (the second peak was >10% away from the first one) were defined as aneuploid. The DNA index (DI) was obtained by calculating the ratio of the mean channel number of the abnormal aneuploid G0/G1 peak to the mean channel number of the normal (diploid) G0/G1 peak. The moles were classified according to the DI of the main peak. 28 Histograms exhibiting a G0/G1 main peak at 2C were considered diploid (index, 0.85-1.15). A sample was considered tetraploid when the main peak was between 1.70 and 2.30. Similarly, a triploid sample was defined by an index between 1.30 and 1.55.
Immunohistochemistry
Immunohistochemical staining was done using a streptavidin-biotin immunoperoxidase complex method. The 5-μm-thick sections from histologically diagnosed cases were transferred to adhesive slides from representative formalin-fixed, paraffin-embedded blocks. The sections were deparaffinized in xylene and dehydrated through a series of graded ethanol. Endogenous peroxidase activity was blocked by incubation with 3% hydrogen peroxide for 30 minutes at room temperature. Antigen retrieval was done by microwave treatment (800 W) for 10 minutes using 0.01 mol/L sodium citrate buffer, pH 6.0 (p57, Ki-67, E-cadherin, and Twist1). The slides were then left to cool at room temperature. Tissue sections were then incubated with anti-p57kip2 mouse monoclonal antibody (clone KP39, 1:100 dilution; Thermo Fisher Scientific, Fair Lawn, NJ) for 60 minutes, rabbit polyclonal antibody Ki-67 (Ready-to-use; Thermo Fisher Scientific) for 30 minutes, mouse monoclonal antibody E-cadherin (clone SPM471, 1:100 dilution; Thermo Fisher Scientific) for 30 minutes, and rabbit polyclonal antibody Twist1 (1:500 dilution; Abcam, Cambridge, UK) for 30 minutes. This was followed by incubation with biotinylated secondary antibody for 30 minutes at room temperature. Visualization of the reaction was performed with an avidin-biotin complex immunoperoxidase system using 3,3′ diaminobenzidine as a chromogen (Sigma-Aldrich). Sections were then counterstained with Mayer's hematoxylin, dehydrated, cleared, and mounted with distyrene, plasticizer, and xylene. Negative control sections were treated with PBS instead of primary antibody. Human breast carcinoma was used as a positive control for Ki-67, colon carcinoma was used for E-cadherin, and normal decidual stromal cells and/or intermediate trophoblastic cells served as internal positive controls for p57.
Scoring of Immunostaining
For evaluation of p57 immunoreactivity, the presence or absence of nuclear positivity was assessed in villous stromal cells, cytotrophoblasts, intermediate trophoblasts, and maternal decidua. The p57 immunoreactivity was interpreted as satisfactorily negative when villous stromal cells and cytotrophoblasts were entirely negative or demonstrated only limited expression (nuclear staining <10% of these cell types) with internal positive control (maternal decidua and/or intermediate trophoblastic cells exhibiting nuclear expression of p57). Positive p57 immunoreactivity was interpreted when the extent of staining in these cell types was extensive or diffuse. For Ki-67, immunoreactivity was assessed in villous cytotrophoblasts by counting 100 cells per slide. The immunoreactivity was assessed as 0 (no stained cells), low (+; ≤25% positive cells), moderate (++; 26%-50% positive cells), and high (+++; >50% positive cells). The expression pattern of E-cadherin was membranous staining, which served as the criterion for positivity. Expression was scored semiquantitatively by evaluating the staining intensity, percentage of positive cells, and E-cadherin immunoreactivity score (EIRS). The EIRS was calculated by multiplying the percentage of positive cells by the staining intensity. Percentage of positive cells was estimated by counting approximately 100 cells per slide (×400 magnification) and scored as follows: 0 = less than 5% staining, 1 = 5% to 25% staining, 2 = 25% to 50% staining, 3 = 50% to 75% staining, and 4 = more than 75% staining. The staining intensity was scored as follows: 0, negative; 1, weakly positive; 2, moderately positive; and 3, strongly positive. Regarding Twist1 immunoreactivity evaluation, the percentages of nuclei immunolabeled by Twist1 in the whole section area were calculated. The immunoreactivity was assessed separately in stromal villi cells and trophoblastic cells. Staining intensity was evaluated as follows: score 0, no staining; score 33, weak nuclear staining; score 66, moderate nuclear staining; and score 100, strong nuclear staining. Finally, a comprehensive score was done by averaging between percentages of immunolabeled cells and staining intensity. Cases were then confirmed to be diagnosed as CHM, PHM, and HA according to concordant results through coupling the initial histopathologic diagnosis with the results obtained by p57 immunohistochemistry and flow cytometry (histologically diagnosed CHM is diploid and lacks p57, whereas a diploid HA would be p57 positive, and PHM is triploid and shows immunoreactivity for p57). However, cases with discordant results were excluded from the statistical analysis and interpreted separately.
Statistical Analysis
Data were analyzed using SPSS software (SPSS 19.0; SPSS, Chicago, IL). The results were expressed as mean ± SD and range of various variables. The Kruskal-Wallis test was used to compare numerical data of antibody expression in different groups. A proven significant result was tested using pairwise comparison by the Mann-Whitney test. Spearman ρ correlation was used to determine the correlation between different examined antibodies. All tests were two-sided at a significance level of P < .05. The sensitivity and specificity, positive predictive value (PPV) and negative predictive value (NPV), and the accuracy of Twist1, Ki-67, and E-cadherin expression were calculated.
Results
According to the histopathologic diagnosis of the total selected cases (55), 19 (34.5%) were identified as CHM, 19 (34.5%) as PHM, and 17 (31.0%) as HA.
Ploidy Analysis
Of the histologically identified cases of CHM (19) , 17 cases showed a diploid histogram pattern, while the two other cases were either tetraploid or triploid. Of 19 cases of PHM, 18 exhibited a triploid pattern, and the remaining case was nontriploid (diploid). Also, 16 of 17 cases of HA exhibited a nontriploid pattern, and one case failed the analysis ❚Figure 1❚.
p57 Immmunostaining
Sixteen of the 19 histologically diagnosed CHM cases showed no p57 immunoreactivity in the villous cytotrophoblast or the syncytiotrophoblast ❚Image 1A❚. Only one case displayed nuclear immunoreactivity in the cytotrophoblast. The remaining two cases showed unsatisfactory negative results. Of the 19 cases of PHM, 18 showed clear p57 immunoreactivity in the cytotrophoblast, and the remaining case revealed negative p57 staining with the positive internal control. All of the 17 HA cases exhibited positive p57 immunoreactivity in the cytotrophoblast and negative expression in the syncytiotrophoblast ❚Image 1B❚.
Finally, coupling the initial histopathologic diagnosis with the results obtained by p57 immunohistochemistry and flow cytometry (CHM is a diploid lacking p57 expression, HA is a diploid positive for p57, and PHM is a triploid positive for p57), 49 cases were confirmed with concordant results (16 cases of CHM, 16 cases of HA, and 17 cases of PHM), and only six cases showed discordant results. These six cases, which we will refer to as problematic cases, were excluded from the statistical analysis and interpreted separately.
Demographic Data
Among 49 confirmed studied cases, the age of patients with CHM ranged from 19 to 48 years with a mean ± SD of 33.3 ± 8.9 years. The mean ± SD age was 23.3 ± 7.1 years in the PHM group and 27 ± 11.6 years in the HA group. There was a significant difference in the mean age of the patients in each case group (P = .01). Noteworthy, all patients older than 47 years had CHM.
The mean gestational age at presentation was comparable among the three case groups (P = .436), being
❚Figure 1❚ Representative examples of (A) a diploid (Dip) observed in hydropic abortion and complete moles, (B) a triploid observed in partial moles, and (C) a tetraploid observed in complete moles on histograms produced by flow cytometry. 
Immunoreactivity
Twist1 Immunoreactivity
All CHM cases were stromal positive for Twist1 expression. The mean comprehensive score for CHM was 84.7 (range, 73-95) ❚Image 2A❚. Fourteen PHM cases showed a weak positivity in stromal villi cells, while three cases were negative. The mean comprehensive score for PHM was 23.7 (range, 0-39). In the HA cases, only four were positive with weak intensity in stromal villi cells. The mean comprehensive score for the HA cases was 6 (range, 0-29).
Stromal Twist1 immunoreactivity expression in the three groups is shown in ❚Table 1❚. The three groups were significantly different in stromal immunostaining score (P < .001). CHM was significantly higher than PHM (P < .001), which in turn was significantly higher than HA (P < .001). CHM cases had values of 73 or above, while the highest value for both diseases was 39. Thus, any value as high as 73 is considered CHM.
Trophoblastic Twist1 immunoreactivity was observed only in syncytiotrophoblastic cells. It was positive in 50% of the HA cases and 47.1% of the PHM cases, as shown in ❚Image 2B❚, but no positive trophoblastic cells were detected in the CHM cases (Image 2A). The mean comprehensive score was 13.1 (range, 0-39) for HA and 14.9 (range, 0-31.5) for PHM. No significant difference was identified between PHM and HA (P = .6), as shown in Table 1 .
Receiver operating characteristic (ROC) curve analysis of Twist1 immunoreactivity in stromal villi cells, using the best comprehensive score for Twist1 to differentiate between CHM and HA/PHM with 73 or higher as a cutoff value, showed an area under curve (AUC) with a value of 1, a sensitivity and specificity of 100%, an NPV and a PPV of 100%, and an accuracy of 100% to predict CHM from HA/PHM ❚Figure 2❚ and ❚Table 2❚.
Regarding analysis of the correlation between both stromal and trophoblast immunoreactivity scores, there was a significant negative correlation between stromal positivity with a cutoff of 73 or more and trophoblast immunoreactivity (r = -0.34, P = .001), as shown in ❚Figure 3❚. We observed that all cases with stromal positivity with a score of 73 or higher (CHM cases) were trophoblast negative, while cases with stromal positivity with a cutoff of less than 73 (PHM/HA cases) showed either trophoblastic positivity or negativity.
Ki-67 Immunoreactivity
Positive Ki-67 expression was observed in the nuclei of cytotrophoblastic cells and intermediate trophoblasts, © American Society for Clinical Pathology while syncytiotrophoblasts were negative for Ki-67 immunostaining with few weak nuclear staining was observed in the stromal cells ❚Image 3A❚ and ❚Image 3B❚. Ki-67 expression in the three groups is shown in Table 1 . There was a significant difference between the three groups, with higher expression in CHM compared with PHM and in PHM compared with HA (P < .001).
In CHM cases, Ki-67 immunoexpression was positive in all cases (100%), with a mean ± SD of 60.6 ± 20.2 and a range of 30% to 90% positive cells. Ten (62.5%) cases showed a high score (+++), while the remaining six cases showed a moderate score (++). In PHM cases, the range of Ki-67 immunoexpression was 10% to 50%, with a mean ± SD of 24.1 ± 11.8. Ki-67 expression with low score (+) was seen in 11 (64.7%) cases, and six cases had a moderate score. No high-score cases were identified.
Regarding HA cases, Ki-67 expression was negative in two (12.5%) cases and positive in 14 (87.5%). All positive cases had a low score; the mean ± SD of Ki-67 immunoexpression was 2.1 ± 4.4, with a range of 0% to 20% positive cells (Table 1) . Also, it was evident that there was an overlap in score (+) between PHM and HA, whereas 44% of low-score cases were PHM while the remaining 56% were HA cases. Also, regarding cases with a moderate (++) score, 50% were PHM cases and the other 50% cases were CHM cases ❚Figure 4❚.
Using ROC analysis to distinguish between PHM and HA cases, at a cutoff value of 20% or more for Ki-67 in cytotrophoblast cells, the AUC was 0.97 (confidence interval, 0.93-1) ❚Figure 5❚ with a sensitivity of 82.4%, a specificity of 93.7%, a PPV of 93.3%, an NPV of 83.3%, and an accuracy of 87.8%. ❚Figure 3❚ Correlation between Twist1 stromal and trophoblastic immunohistochemical score. Spearman rank correlation coefficient, significant at P < .05; negative correlation, r = 0.34, P = .001.
❚Figure 2❚ Receiver operating characteristic curve of Twist1 stromal expression in the prediction of complete hydatidiform mole vs partial hydatidiform mole and hydropic abortion. Table 1 . EIRS expression was significantly higher in PHM compared with CHM (P < .001) and significantly higher in HA compared with PHM (P < .001). There was no significant difference between CHM and PHM (P = .07).
In CHM cases, the range of EIRS was 1 to 6, with a mean ± SD of 2.4 ± 1.7; 87.5% of the cases were within the very low EIRS (score 1 and 2) and low EIRS (score 3 and 4). Only two cases resulted in a moderate EIRS (score 6 and 8). Regarding PHM cases, the mean ± SD EIRS was 3.8 ± 1.4 (range, 2-8). Most of the EIRS in PHM cases was observed within the low category (score 3 and 4), forming 70.6% of PHM cases, while only two cases had a moderate EIRS (score 6 and 8). In HA cases, the range of EIRS was 2 to 12, with a mean ± SD of 8.3 ± 3. Of the cases, 56.3% showed a high EIRS (score 9 and 12), 37.5% exhibited a moderate EIRS (score 6 and 8), and only one case had a low EIRS (score 3 and 4) ❚Image 4❚ and ❚Figure 6❚.
Using ROC analysis to distinguish between PHM and HA cases, at a cutoff value of 4 or less for E-cadherin ❚Image 2❚ A, Positive Twist1 stromal expression in complete hydatidiform mole with negative trophoblastic immunoreactivity (×200). B, Positive Twist1 expression (both stromal and trophoblastic) in hydropic abortion (×200). 
Correlation Between Immunohistochemical Markers (Ki-67 and E-Cadherin) in PM and HA Groups
A significant negative correlation was observed between Ki-67 and E-cadherin (r = -0.64, P = .001) in both PHM and HA cases ❚Figure 8❚.
Combined Ki-67 and E-Cadherin Immunophenotypes
According to the best cutoff values of both Ki-67 and E-cadherin for differentiating PHM and HA, four immunophenotypes for combined expression patterns of both markers were identified (Ki-67 ≥20, EIRS ≤4; Ki-67 <20, EIRS >4; Ki-67 ≥20, EIRS >4; and Ki-67 <20, EIRS ≤4). None of PHM cases exhibited a Ki-67 of less than 20 and an EIRS of more than 4, while 70.6% of PHM cases showed expression of a Ki-67 of 20 or higher and an EIRS of 4 or less. Within HA cases, 87.6% exhibited a Ki-67 of less than 20 and an EIRS of more than 4, and only one case showed a Ki-67 of 20 or more and an EIRS of 4 or less ❚Table 3❚.
Diagnostic Validity of Combined Ki-67 and E-Cadherin Expression in Diagnosis of PHM in Comparison to HA Cases
Building an ROC curve by using combined Ki-67 and EIRS for differentiation of PHM and HA is presented in ❚Figure 9❚. This curve was done on 27 of 33 cases of both PHM and HA, which represent concordant negatively correlated combined results (Ki-67 ≥20 and EIRS ≤4 and Ki-67 <20 and EIRS >4). Six cases were excluded as they do not conform to the previously proven negative correlation between both markers. The AUC was 0.96 ± 0.03 (confidence interval, 0.89-1; P = .001), with a sensitivity of 100%, a specificity of 93.3%, an NPV of 100%, a PPV of 92.3%, and an accuracy of 96.2% ❚Table 4❚. 
Cases Characteristics and Results of the Six Problematic Cases
In this study, six cases show discordant results. Data regarding the original histopathologic diagnosis, the results obtained by p57 immunohistochemistry, flow cytometry analysis, and expression pattern for Twist1, Ki-67, and E-cadherin for each case are shown in ❚Table 5❚.
Discussion
Flow cytometric analysis of DNA ploidy was carried out for 55 specimens of histologically diagnosed cases of CHM, PHM, and HA. Among cases initially diagnosed as CHM, 89.5% (17/19) exhibited a diploid histogram pattern, while for PHM, 94.7% (18/19) exhibited a triploid pattern. Similar findings were reported by Crisp et al 8 for CHM, in which 95.5% of cases exhibited diploid patterns, as confirmed by flow cytometry and image cytometry. However, they reported a higher incidence of diploid patterns in PHM (up to 25%) compared with our study (5%). This difference may be explained by the possibility of the presence of extensive maternal cell contamination that might diminish the percentage of triploid cells on the histogram.
Additional use of p57 immunostaining with DNA ploidy analysis has slightly modified the diagnostic outcome in cases of HM, seemingly toward more specificity. For CHM, lack of p57 expression was confirmed in 16 (84.2%) of the 19 histologically identified cases in the presence of a satisfactory positive control. Vang et al 29 reported that the p57 immunostain enhanced the sensitivity of a diagnosed CHM from 93% to 96% for individual pathologists and 96% by consensus. Moreover, the specificity has improved from 96% to 98% for individual pathologists and 96% by consensus with Combining p57 immunostaining with DNA ploidy analysis seems to draw a plausible model for differentiation of HM from HA and for the classification of HM (HA is a diploid positive for p57, CHM is a diploid lacking p57 expression, and PHM is a triploid positive for p57). [29] [30] [31] [32] However, this model was only robust for a total of 49 (89.1%) of 55 studied cases. The remaining six cases have shown discordant results (Table 5) : these included three cases of CHM (a p57-positive case and two cases with technically unsatisfactory p57 expression), two cases of PHM (a diploid case and a p57-negative triploid case), and one HA case (a p57-positive case with unsatisfactory genotype analysis). This finding indicates that some "problematic cases" are capable of challenging the ploidy-p57 model, indicating the need to have more differential molecular targets for a more absolute distinction. To this end, our findings show that Twist1 can be useful in differentiating CHM from HA and PHM. Based on using ROC curve analysis of the twist immunoreactivity in stromal villi cells, a cutoff of 73 or higher attained the best comprehensive score of Twist1 to differentiate between CHM and HA/ PHM with 100% sensitivity, 100% specificity, 100% NPV, 100% PPV, and 100% accuracy. In addition, we did find that all of these cases, which showed stromal positivity with a score of 73 or higher (CHM cases), were trophoblast negative. Thus, the combination of trophoblastic negativity results with stromal positivity of 73 or more might be a good confirmatory diagnostic method to exclude cases with CHM. These results were quite similar to those found by Luchini et al, 33 who analyzed the immunohistochemical expression of Twist1 and Snail2 among CHM, PHM, and abortion cases. They found that Twist1 and Snail2 were highly expressed in stromal villi cells of molar disease. 33 In particular, Twist1 was highly expressed in CHM compared with both abortive pregnancies and PHM. Our cutoff point values with an accuracy of 100% were 33 This could be explained by the variability of an objective assessment in scoring and using different clones with diverse concentrations of the marker.
In addition, our study shows that Ki-67 is useful for distinguishing HA from PHM cases, and Ki-67 immunoreactivity in cytotrophoblastic cells has been used as the best index to separate the different groups in this study. Our results demonstrated that Ki-67 immunoreactivity in cytotrophoblastic cells significantly differed between the molar and nonmolar specimens and between CHM and PHM as well. This is consistent with previous reports. [34] [35] [36] However, conflicting results obtained by different studies demonstrated that the Ki-67 labeling index differed significantly between the molar and nonmolar placentas, with no distinction between PHM and CHM. 37 Conversely, it has been documented that Ki-67 is considered a good marker in differentiating CHM from PHM but not PHM from HA. 38 These conflicting findings may be related to variation in detection methods and techniques or the presence of different clones of the marker. Moreover, despite the significant differences between the three tested groups in our study, an overlap of Ki-67 expression was found between PHM and HA in the low score (+) and moderate score ❚Figure 8❚ Correlation between Ki-67 immunoexpression and E-cadherin immunoreactivity score (EIRS) in both partial hydatidiform mole and hydropic abortion groups.
❚Figure 6❚ Distribution of E-cadherin immunoreactivity (EIRS) scores among different groups: very low (score 1 and 2), low (score 3 and 4), moderate (score 6 and 8), and high (score 9 and 12). CHM, complete hydatidiform mole; HA, hydropic abortion; PHM, partial hydatidiform mole. (++) between PHM and CHM cases. This overlap might impede the proper utility of this marker as a diagnostic test to distinguish one group from another. So by reviewing the results mentioned above, the achieved Ki-67 immunostaining results could be applied by using ROC curves to evaluate the exact prognostic value of Ki-67 immunoreactivity to distinguish HA from PHM cases. Based on the Ki-67 cutoff point of 20% or more in cytotrophoblastic cells, overall sensitivity, specificity, and PPV for detecting HA from PHM were 82.4%, 93.7%, and 93.3%, respectively.
Regarding E-cadherin immunoexpression among different groups, a significant difference has been observed by comparing EIRS in different groups (P < .001), specifically between partial hydatidiform moles and hydropic abortions (P3 < .001). However, an overlap has been detected in the expression pattern of very low, low, and moderate EIRS between PHM and HA cases. Furthermore, the difference between CHM and PHM did not reach a significant level (P1 = .07). In this respect, Xue et al 39 reported a similar result by which E-cadherin immunoreactivity was reduced in choriocarcinoma and CHM compared with the normal first-trimester placenta and displayed no significant difference between CHM and PHM cases. However, a recent report revealed that a marked decline in the expression pattern of E-cadherin from HAs to PHMs to CHMs has been observed. 40 Another study demonstrated that E-cadherin decreased gradually from normal villous trophoblasts in early pregnancy to benign HM to invasive HM. However, no subclassification of benign HM has been made. 41 All these findings suggest that the disturbance of chorionic integrity with uncontrolled proliferation and invasiveness of trophoblastic cells in HMs might be, in part, attributable to the loss of E-cadherin-mediated adhesion. Our study also demonstrated that despite the significant difference in E-cadherin immunoreactivity, especially among PHM and HA cases, there was an overlap in the expression pattern of very low, low, and moderate EIRS between PHM and HA cases. This overlap might render the possibility of using this marker to distinguish between the studied groups. Therefore, ROC curves have been used to determine the cutoff point, sensitivity, and specificity of EIRS in differentiating between cases of PHM and nonmolar pregnancies. The best cutoff point for differentiation of PHM and HA was an EIRS of 4 or less, with 88.2% sensitivity, 87.6% specificity, 87.6% NPV, 88.2% PPV, and 87.8% accuracy.
Combining existing tests has been used as a strategy to improve the diagnostic accuracy of a single test. To our knowledge, this is the first study that estimated the accuracy of combined Ki-67 immunoreactivity and EIRS with analysis of the NPV and PPV of these approaches in differentiating between previously studied PHM and HA cases. When both Ki-67 immunoreactivity and EIRS tests were used together, global sensitivity reached 100%, while global specificity remained at 93.3%. PPV was 92.3%, and NPV attained 100% with 96.2% accuracy. Concerning these results, all cases with a combination Ki-67 of less than 20 and an EIRS of more than 4 should be excluded as PHM (NPV 100%), and all cases with a Ki-67 of 20 or more and an EIRS of 4 or less could be diagnosed as PHM with 92.3% PPV. These results demonstrated the possibility of improving the diagnostic accuracy of differentiating PHM cases from HA cases through the use of a combined Ki-67 and E-cadherin approach. However, few discordant combined (Ki-67, E-cadherin) results that represent less than 18% of cases could not be used to differentiate between PHM and HA cases, and in this situation, we have to return to the traditional substitute, which is the ploidy analysis. The accuracy of the two combined tests in sequence still led to reasonable sensitivity and specificity for the differentiation between two groups regarding low socioeconomic status, which may not allow use of additional other sophisticated genetic tests such as FC in most cases.
Combining variable diagnostic markers could offer a tool to explain the six problematic cases discussed earlier. The first discordant CHM case, which demonstrated a triploid DNA pattern and positive expression of p57, could be reclassified as PHM. This is in line with the results obtained by Twist1 expression in both stromal villi with 34% positivity and 26% trophoblast positivity for this case, which reinforces the exclusion of the original diagnosis as CHM. At the same time, the results of both Ki-67 and EIRS enforce the diagnosis of PHM (Ki-67 ≥20 and EIRS ≤4) with a PPV of 92.3%. The second two discordant CHM cases showed technically ❚Figure 9❚ Receiver operating characteristic curve of combined Ki-67/E-cadherin immunoreactivity score (EIRS) immunostaining expression (Ki-67 ≥20 and EIRS ≤4) for differentiation between partial hydatidiform mole and hydropic abortion.
DOI: 10.1093/ajcp/aqy012 © American Society for Clinical Pathology unsatisfactory p57 expression due to the lack of a positive internal control. The first case displayed a diploid pattern, and the second one showed a tetraploid pattern. Based on the Twist1 expression, both cases showed 85% and 95% concurrent stromal positivity, respectively, with 0% trophoblast positivity for both. These findings confirm the original diagnosis of CHM with 100% PPV. Analysis of both Ki-67 and E-cadherin in both cases showed high Ki-67 expression and low EIRS that come in accordance with the results of cases with molar changes. One of the two discordant PHM cases showed a triploid pattern with negative satisfactory expression of p57. In this case, Twist1 expression was positive in both stromal villi with 39% positivity and 29% positivity of trophoblasts, leading to the exclusion of the original diagnosis of CHM, which might be suspected if it depends on p57 alone without coupled ploidy analysis. The lack of p57 expression can be explained by the loss of the maternal copy of chromosome 11. 18 The results of both Ki-67 and EIRS suggest the diagnosis of PHM (Ki-67 ≥20 and EIRS ≤4) with a PPV of 92.3%. The second discordant PHM case had a diploid pattern and positive p57. Based on this pattern, this case should be rediagnosed as HA. Twist1 expression, in this case, indicated that the result of the stromal positivity rate only comes in accordance with the positivity of p57 to confirm the exclusion of CHM, which shows that a positivity rate of less than 73% is the best cutoff with 100% NPV to exclude CHM. However, trophoblastic negativity could not be used as a significant feature with that stromal positivity rate. Analysis of low Ki-67 and high E-cadherin expression, in this case, resulted in 100% NPV, which leads to exclusion of the diagnosis of partial mole. Therefore, both Ki-67 and E-cadherin (Ki-67 <20 and EIRS >4) can give similar results compared with the result obtained by ploidy analysis in differentiating HA from PHM cases.
The last problematic case, which showed unsatisfactory genotypic results due to the insufficient number of villi and positive p57 expression, was detected in the HA group. Based on the p57 expression result alone, this case should be diagnosed as HA. The analysis of Twist1 expression displayed expression in both stromal villi, with 19% positivity and 21% positivity of trophoblasts. These results can exclude the possibility of CHM. However, both Ki-67 and E-cadherin expression (Ki-67 ≥20 and EIRS ≤4) in this case give a PPV of 92.3% to rediagnose this case as PHM.
Conclusions
In this study, our findings can add additional support and strength for an algorithm that combines p57 immunohistochemistry and molecular genotyping for the differential diagnosis of molar and nonmolar gestations, particularly by combining both Twist1 and p57 to solve the unsatisfactory outcomes that might be obtained with the p57 immunostain. Moreover, this study tried to find an alternative acceptable approach for the molecular genotyping procedure by using both Ki-67 and E-cadherin immunoreactivity to distinguish a PHM from nonmolar pregnancies, especially HA cases, with a good sensitivity and specificity for the differentiation between two groups. Comparing with these molecular methods that is often unlikely to be used as routine laboratory methods because of their time-consuming processes and high cost. Therefore, the combination of immunohistochemistry can reduce both time and high cost, especially in developing countries with low availability of equipment and income. In summary, ancillary techniques still can substantially improve the diagnosis of molar pregnancies. Immunohistochemical staining using Twist1 is very useful in identifying most cases of CHM, and a combined Ki-67 and E-cadherin approach can provide an acceptable alternative assay for the differential diagnosis of PHM and HA in difficult cases, particularly.
